Advertisement

PharmacoEconomics & Outcomes News

, Volume 836, Issue 1, pp 5–5 | Cite as

Baricitinib less costly treatment option in moderate-to-severe RA

Clinical study
  • 7 Downloads

Reference

  1. Wehler E, et al. A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA. PharmacoEconomics : 27 Aug 2019. Available from: URL: https://doi.org/10.1007/s40273-019-00829-x

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations